From KFF Health News Network – Their latest podcast, What the Health, A week into the reorganization of the Department of Health and Human Services announced by Secretary Robert F. Kennedy Jr., the scope of the staff cuts and program cutbacks is starting to become clear.
From KFF Health News Network – Their latest podcast, What the Health, The second Trump presidency launched with a bang at the Department of Health and Human Services, where a traditional pause on public communications was expanded to an effective stoppage of scientific work, as health agencies were ordered to cancel meetings, travel, and efforts on outside publications.
By Robert M. Califf MD – One of the most alarming changes is the recent decline in life expectancy in our country, largely due to the cumulative impact of CCDs, combined with excessive rates of suicide, drug overdose and gun violence, and, of course, COVID-19. How can it be that our prowess in technology is not translating into better health and longevity for the American public?
By Robert M. Califf MD – Since launching our Overdose Prevention Framework in August, 2022, the FDA has taken some important steps to address the opioid overdose crisis. I’d like to catch up with you about opioid use disorder, and efforts we’re taking to mitigate this ongoing health condition.
By Robert M Califf MD & Kaveeta P. Vasisht MD PharmD – Thirty years ago, the U.S. Food and Drug Administration’s Office of Women’s Health was established to promote the inclusion of women in clinical trials and to provide leadership on topics related to the health of women.
By David Hilzenrath & Holly K. Hacker – When the FDA recently convened a committee of advisers to assess a cardiac device made by Abbott, the agency didn’t disclose that most of them had received payments from the company or conducted research it had funded — information readily available in a federal database.
By Robert Califf – At the FDA, we’ve been working for years to anticipate and prepare for the challenges of Artificial Intelligence (AI), and also to harness its potential. Some in the nonscientific community may be surprised by the seemingly sudden amount of attention on AI.
By Robert Califf – Recently I wrote about my recent trip to India, a trip largely motivated by the enormous need for coordinated effort on the common imperative in the U.S. and the rest of the world for readily available, high-quality generic drugs. I also relished the chance to visit a fascinating country and renew many friendships.
By Robert M. Califf MD – Biomedical and healthcare progress is dependent upon research that informs our decisions. The clinical trial is the most reliable method to determine the benefits and risks of interventions. The formation of ClinicalTrials.gov in February 2000 was a major step forward by providing a public record of trials.
By Robert M. Califf MD – Recently I marked my one-year anniversary as the 25th Commissioner for Food and Drugs. I have been proud to represent the U.S. Food and Drug Administration and its talented and hard-working staff in these extraordinary times.
CMS is releasing the following statement from Administrator Chiquita Brooks-LaSure, with accompanying background information, in response to the action by the FDA to grant accelerated approval to a new product designed to treat Alzheimer’s disease.
By Robert M. Califf MD – National Immunization Awareness Month provides us an opportunity to think about how far the development and advancement of immunization science has come, and its impact on public health.
©2025 Answers Media Company, LLC
Notifications